FDA clears ArteraAI Breast for breast cancer risk stratification

The U.S. Food and Drug Administration has cleared ArteraAI Breast for use in patients with early-stage, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative invasive breast cancer.